obesity drugs

Sep 02, 2025

FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

May 12, 2025

9 Promising Obesity Drugs Set to Launch by 2030

Apr 29, 2025

Boston Scientific Pushes Forward Despite $200M Tariff Challenge; Northstrive Biosciences Gets FDA Green Light to Advance EL-22 Obesity Trial; Roche Acts Swiftly to Offset U.S. Tariff Impact with Global Engagements; Verastem Oncology Secures IND Clearance for KRAS G12D Inhibitor Trial; BlackfinBio Gets FDA OK for Phase I/II Trial of BFB-101 in SPG47

Mar 26, 2025

The Latest Breakthroughs in Obesity Treatment: A New Era of Weight Loss Innovation

Mar 17, 2025

Novo Nordisk vs. Eli Lilly: The Battle for Anti-Obesity Drug Market Dominance

Mar 14, 2025

Obesity Treatment: Which Pipeline Therapy Will Revolutionize the Therapeutics Segment?

Mar 12, 2025

The Race to Redefine Obesity Treatment

Mar 12, 2025

WEGOVY: A Leader in the Obesity and Weight Loss Treatment

Mar 12, 2025

8 Emerging Obesity Trends Transforming Therapeutics Segment

Mar 12, 2025

How Bariatric Surgery Devices Are Revolutionizing Weight Loss Outcomes?

Newsletter/Whitepaper